

Regimen Name on NCCP			
Date Launched	website	Tumour Group	Regimen Number
10/03/2023	Pertuzumab Trastuzumab (Phesgo®) and vinORELbine	Breast	798
	Bevacizumab 15mg/kg, PACLitaxel 175mg/m2 and CISplatin 50mg/m2 Therapy	Gynaecology	799
	Cemiplimab Therapy	Gynaecology	812
14/04/2023	Pertuzumab/Trastuzumab (Phesgo®), PACLitaxel and CARBOplatin Therapy (TRAIN-2)	Breast	790
17/04/2023	Pembrolizumab, PACLitaxel 175mg/m2, CARBOplatin AUC 5 and Bevacizumab Therapy	Gynaecology	811
	Pembrolizumab, PACLitaxel 175mg/m2 and CARBOplatin AUC 5 Therapy	Gynaecology	817
01/05/2023	(R*)-ICE ((riTUXimab*), Ifosfamide, CARBOplatin and Etoposide) Therapy - Outpatient	Lymphoma	751
02/05/2023	Cemiplimab Therapy	Skin/Melanoma	812
	Bevacizumab 5mg/kg Monotherapy – 14 Day	Neuro-oncology	813
11/05/2023	PACLitaxel 80 (7 day) and Trastuzumab (21 day) Therapy	Breast	815
15/05/2023	Lomustine and Bevacizumab 7.5mg/kg Therapy	Neuro-oncology	804
	Lomustine 130mg/m2 Therapy	Neuro-oncology	805
	CISplatin, Lomustine and vinCRISline (CLV) Therapy	Neuro-oncology	806
01/06/2023	Pembrolizumab 200mg, CISplatin 80mg/m2 and 5-Fluorouracil Infusional Therapy	Gastrointestinal	739
28/06/2023	Nivolumab 240mg, CISplatin 80mg/m2 and 5-Fluorouracil Infusional Therapy	Gastrointestinal	816
	Nivolumab 480mg, CISplatin 80mg/m2 and 5-Fluorouracil Infusional Therapy	Gastrointestinal	832